Bicocca Open Archive

Logo unimib boa
CAZZANIGA, MARINA ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.509
EU - Europa 2.742
AS - Asia 673
SA - Sud America 9
AF - Africa 8
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 3
Totale 8.951
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.441
IT - Italia 848
DE - Germania 563
IE - Irlanda 496
SE - Svezia 368
CN - Cina 287
HK - Hong Kong 237
UA - Ucraina 113
GB - Regno Unito 105
CA - Canada 66
IN - India 54
DK - Danimarca 53
AT - Austria 47
FI - Finlandia 45
VN - Vietnam 38
RU - Federazione Russa 26
FR - Francia 25
TR - Turchia 21
BE - Belgio 13
NL - Olanda 13
IR - Iran 8
JP - Giappone 7
SG - Singapore 6
BR - Brasile 5
RO - Romania 5
SC - Seychelles 5
CH - Svizzera 4
ES - Italia 4
EU - Europa 4
PK - Pakistan 4
SK - Slovacchia (Repubblica Slovacca) 4
AU - Australia 3
BG - Bulgaria 3
CL - Cile 3
A1 - Anonimo 2
CZ - Repubblica Ceca 2
ID - Indonesia 2
KR - Corea 2
MU - Mauritius 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BD - Bangladesh 1
CR - Costa Rica 1
EC - Ecuador 1
GR - Grecia 1
HN - Honduras 1
IL - Israele 1
LT - Lituania 1
MD - Moldavia 1
ME - Montenegro 1
MM - Myanmar 1
MN - Mongolia 1
SI - Slovenia 1
TW - Taiwan 1
UZ - Uzbekistan 1
ZA - Sudafrica 1
Totale 8.951
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.732
Fairfield 505
Dublin 484
Frankfurt am Main 448
Chandler 367
Wilmington 342
Woodbridge 300
Milan 271
Ashburn 269
Houston 246
Hong Kong 233
New York 227
Seattle 183
Cambridge 182
Princeton 158
Jacksonville 109
Dearborn 86
Lawrence 73
Altamura 72
San Diego 50
Vienna 47
Beijing 39
Guangzhou 38
Shanghai 34
Rome 33
Andover 32
Nanjing 32
London 31
Helsinki 25
Dong Ket 22
Falls Church 21
Lissone 21
Toronto 20
Boardman 17
Kocaeli 17
Pune 17
Hebei 16
Chicago 15
Lachine 14
Ottawa 14
Tianjin 14
Brussels 13
Jinan 13
Hangzhou 12
Carate Brianza 11
Monza 11
Edmonton 10
Nanchang 10
Norwalk 10
Desio 9
Council Bluffs 8
Shenyang 8
Turin 8
Zhengzhou 8
Potenza 7
Redmond 7
Chengdu 6
Hyderabad 6
Kunming 6
Lecco 6
Shenzhen 6
Torre Del Greco 6
Wuhan 6
Amsterdam 5
Atlanta 5
Bergamo 5
Bologna 5
Capaccio 5
Fremont 5
Hounslow 5
Islington 5
Lappeenranta 5
Los Angeles 5
Marietta 5
Mumbai 5
Palermo 5
Upper Marlboro 5
Washington 5
Brescia 4
Changsha 4
Cinisello Balsamo 4
Edinburgh 4
Esslingen am Neckar 4
Leawood 4
Marano di Napoli 4
Napoli 4
Padova 4
Perugia 4
Taizhou 4
Torino 4
Ardea 3
Baltimore 3
Broni 3
Caserta 3
Central 3
Corsico 3
Ferrara 3
Florence 3
Gallarate 3
Genoa 3
Totale 7.196
Salva come PNG Salva come JPEG
Nome #
Methotrexate inhibits SARS-CoV-2 virus replication "in vitro" 372
A Multidisciplinary Intervention to Tell Children about the Parent's Cancer: Preliminary Results 280
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. 273
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 235
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 223
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 222
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 219
Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve 213
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 213
Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis 200
Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study 184
Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract 180
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 179
The antiangiogenic effect of the metronomic combination of 5-Fluorouracil plus vinorelbine is mediated by FAK/AKT pathway downregulation and apoptosis activation 169
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients 168
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer 159
"Why my parent is ill?" A specific, multidisciplinary intervention to enhance comunication to cancer patients' children 159
Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study 151
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 149
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study 135
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 134
Long-term course of oxaliplatin-induced polyneuropathy: a prospective two-year follow-up study 134
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients 133
Auto-antibodies against type I IFNs in patients with life-threatening COVID-19 132
Correction: NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (Breast Cancer Research (2019) 21 (133) DOI: 10.1186/s13058-019-1196-y) 127
The significance of dorsal sural nerve recordings in early detecting oxaliplatin-induced peripheral neuropathy. 124
Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study. 124
Mapping the human genetic architecture of COVID-19 118
The role for tocilizumab in covid-19 patients: Reflections on monza cohort data 115
When progressive dysphagia could be related to an “old friend” – a case report 114
Neurofilament light chain serum levels as a possible paclitaxel-induced peripheral neurotoxicity biomarker: pilot and feasibility study. 110
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 109
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 107
Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer 104
Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success 103
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients 102
Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project 101
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 101
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 101
Erratum: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9 (31877-31887) DOI: 10.18632/oncotarget.25874) 99
Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874) 98
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 94
Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future? 94
Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study 92
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 92
NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer 91
Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project 89
Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE 84
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 79
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 70
A possible biomarker for paclitaxel-induced peripheral neurotoxicity: Neurofilament light chain serum levels monitoring 68
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) 68
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study 68
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study 66
Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now? 64
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 63
Adjuvant systemic treatment of early breast cancer: the NORA study 63
Molecular and immune biomarkers for cutaneous melanoma: Current status and future prospects 63
Targeted therapies for the treatment of breast cancer in the post-trastuzumab era 62
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 61
A second update on mapping the human genetic architecture of COVID-19 59
In reply to Kadri Altundag 59
Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers 57
The anthracyclines and the clinical practice: do all breast cancer patients benefit? Results from the NORA study 56
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 55
Efficacy and safety of vinorelbine-capecitabine oral metronomic combinaton in elderly metastatc breast cancer patents: VICTOR-1 study 52
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 52
Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study 52
5-year results of cisplatin-epirubicin-vinorelbine (PEV) combination as primary chemotherapy in T2-3, N0-2 breast cancer patients: a multicentre phase II study 50
Biological characteristics and medical treatment of breast cancer in young women-a featured population: results from the NORA study 50
Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: Management considerations 50
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience 46
Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists? 46
Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic 42
Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials 42
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study 42
Everolimus plus exemestane in advanced breast cancer: Safety results of the BALLET study on patients previously treatedwithout and with chemotherapy in the metastatic setting 38
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab 38
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 37
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9) 37
Metronomic chemotherapy for advanced breast cancer patients 35
Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study 35
Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: Current status and future development 35
Social capital and willingness to participate in COVID-19 vaccine trials: an Italian case-control study 32
Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: A multi-cycle, phase II study 30
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 29
Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study 29
Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows 28
Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer 28
Fulvestrant (FUL) as first-line therapy in HR+ve, HER2-ve advanced breast cancer (ABC) patients (pts): when clinical practice comes earlier than clinical trials. Results from the GIM-13 AMBRA study 28
Metronomic chemotherapy 27
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19 26
Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study 25
Breast cancer in elderly women: a different reality? Results from the NORA study 25
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 21
Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation 20
Diagnosis, management and clinical outcome of bone metastases in breast cancer patients: results from a prospective, multicenter study 19
Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study 19
How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story 18
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) [Trattamento con Gefitinib nei pazienti anziani o con scarso performance status (PS), affetti da carcinoma polmonare non a piccole cellule (NSCLC)] 18
Totale 9.391
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.418
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.418
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019134 0 0 0 0 0 0 0 0 0 0 62 72
2019/20201.335 91 65 51 53 70 94 225 212 192 124 128 30
2020/20212.487 71 208 212 197 183 236 223 356 240 202 175 184
2021/20221.187 123 121 147 87 48 89 62 89 58 74 85 204
2022/20232.066 250 549 161 154 121 267 132 128 95 61 82 66
2023/20241.588 81 74 63 91 248 389 344 57 163 54 24 0
Totale 9.607